Physician profile
Deann M Brown
NPI 1275995912
$3,066.65
in general payments reported to CMS, 2019-2025
25 companies · $77.26 in 2025
The $77.26 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,004 · 2022: $919 · 2023: $624 · 2024: $442 · 2025: $77.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.84 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $430.95 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $375.64 | 2021-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $212.90 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $207.79 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $177.48 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.97 | 2021-2023 | |
| Bausch Health US, LLC | $152.61 | 2021-2022 | |
| Axsome Therapeutics, INC. | $122.95 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $105.60 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $77.04 | 2021-2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $76.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.84 | 2023 | |
| Jazz Pharmaceuticals INC. | $56.35 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.69 | 2023-2024 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.47 | 2023-2024 | Mounjaro |
| Novo Nordisk INC | $36.82 | 2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $34.75 | 2023-2024 | Breztri |
| Almatica Pharma LLC | $33.92 | 2021-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Janssen Pharmaceuticals, INC | $28.55 | 2021 | |
| Eisai INC. | $20.56 | 2022 | |
| Glaxosmithkline, LLC. | $18.56 | 2023 | Shingrix |
| Merck Sharp & Dohme LLC | $15.71 | 2023 | Verquvo, Belsomra |
| Pfizer INC. | $15.41 | 2023 | |
| Ironshore Pharmaceuticals INC. | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deann Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.